CollPlant Expands Vergenix Distribution
Ticker: CLGN · Form: 6-K · Filed: Sep 15, 2025 · CIK: 1631487
Sentiment: neutral
Topics: distribution-expansion, product-launch
TL;DR
CollPlant is pushing Vergenix into new markets, watch for growth.
AI Summary
On September 15, 2025, CollPlant Biotechnologies Ltd. announced an expansion of the distribution of its Vergenix® product line. This expansion will include new markets, though specific details on these markets and the financial impact were not disclosed in this filing.
Why It Matters
Expanding product distribution can lead to increased revenue and market share for CollPlant, potentially benefiting its shareholders.
Risk Assessment
Risk Level: medium — The filing indicates expansion but lacks specific details on new markets or financial projections, introducing uncertainty.
Key Players & Entities
- CollPlant Biotechnologies Ltd. (company) — Registrant
- Vergenix® (product) — Product being distributed
FAQ
What specific new markets is CollPlant expanding Vergenix distribution into?
The filing states that CollPlant is expanding the distribution of its Vergenix® product line into new markets, but does not specify which ones.
When was the press release announcing this expansion issued?
The press release announcing the expansion of Vergenix distribution was issued on September 15, 2025.
What is CollPlant's primary business activity?
CollPlant Biotechnologies Ltd. is involved in the orthopedic, prosthetic & surgical appliances & supplies industry, as indicated by its SIC code 3842.
Does CollPlant file annual reports under Form 20-F or 40-F?
CollPlant Biotechnologies Ltd. files annual reports under cover of Form 20-F.
What is the principal executive office address for CollPlant?
The principal executive office of CollPlant Biotechnologies Ltd. is located at 4 Oppenheimer St, Weizmann Science Park, Rehovot 7670104, Israel.
Filing Stats: 188 words · 1 min read · ~1 pages · Grade level 14.4 · Accepted 2025-09-15 07:24:46
Filing Documents
- ea0257329-6k_collplant.htm (6-K) — 9KB
- ea025732901ex99-1_collplant.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-25-087406.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. COLLPLANT BIOTECHNOLOGIES LTD. Date: September 15, 2025 By: /s/ Eran Rotem Name: Eran Rotem Title: Deputy CEO and Chief Financial Officer 2